The scale of the underlying data collection is considerable. Between 2007 and 2018, the team recruited 250 patients with colon cancer and isolated tumor samples together with matched adjacent normal tissue from each patient. Rather than relying on the methylation arrays that dominate most epigenome-wide association studies, the researchers applied three complementary technologies to the same samples: whole-genome sequencing to read out the complete genetic sequence, whole-genome bisulfite sequencing to measure methylation at essentially every cytosine in the genome, and RNA sequencing to quantify gene expression. This trio of measurements, gathered from both tumor and normal tissue, allowed the team to connect genetic variation, methylation state, and gene activity within the same individuals, an integration that is rarely achieved at this depth in cancer genomics.

The headline result is a catalog of staggering size. By testing which single nucleotide polymorphisms, or SNPs, are statistically associated with methylation levels at nearby CpG sites, the team identified 48,429,542 cis-acting SNP-CpG associations spanning 553,834 meCpGs across the genome, all passing an extremely stringent significance threshold of p less than 2 times 10 to the power of minus 12. In other words, more than half a million methylation sites in the colon cancer genome show measurable genetic control from variants located nearby on the chromosome. This is precisely the kind of resource that has been missing for East Asian populations, where meQTL studies at single-base resolution have been scarce, even though colorectal cancer incidence patterns and genetic architecture can differ from those of European-ancestry cohorts that have dominated the field.

One of the most striking patterns in the data is pleiotropy: the same methylation site is often tugged at by multiple independent genetic variants. Sixty-three percent of the CpGs linked to meQTLs were associated with more than one lead variant, suggesting that methylation at a given cytosine is rarely governed by a single genetic switch. Instead, the epigenetic state of a CpG appears to emerge from the combined influence of several regulatory elements, each contributing its own effect. This layered architecture has practical consequences for interpreting disease genetics, because a variant that nudges methylation slightly may only matter in combination with others, and a GWAS signal attributed to one gene may in fact operate through several methylation targets simultaneously.

The study also connects genetic control to the methylation changes that define cancer itself. Colon tumors differ from normal colon tissue in characteristic patterns of methylation gain and loss, concentrated in differentially methylated regions, or DMRs. When the researchers overlaid their meQTL map onto these tumor-specific DMRs, they found that 16.8 percent of lead meQTLs sit inside regions whose methylation is dysregulated between tumor and normal tissue. That overlap implies a mechanistic bridge: inherited variants may predispose certain genomic locations to the methylation errors that accumulate during tumorigenesis, effectively pre-marking vulnerable sites in the genome long before cancer develops.

To trace the chain of causation from DNA variant to methylation to gene expression, the team turned to colocalization analysis, a statistical method that asks whether two association signals, one for methylation and one for gene expression, are likely driven by the same causal variant rather than by two different variants that merely sit close together on the chromosome. This analysis yielded 14,104 CpG-gene pairs that appear to share a common causal variant. Even more revealing were the mediation analyses built on top of these pairs: the researchers estimated that meQTLs mediate 51 percent of the SNP effects on gene expression. In plain terms, for roughly half of the genetic influences on gene activity that the team could quantify, the effect appears to flow through methylation rather than acting directly on transcription machinery. That makes DNA methylation not merely a passive marker of cancer biology but a major conduit through which inherited sequence variation shapes tumor gene expression.

Pathway analysis of the genes and methylation sites under genetic control pointed to several biological systems with obvious relevance to cancer. The team found epigenetic regulation of pathways involved in translation, RNA polymerase function, and DNA repair. Each of these is a plausible lever on tumor behavior: altered translation rates are a hallmark of many cancers, RNA polymerase activity determines how aggressively genes are transcribed, and defective DNA repair is a classic route to the mutation burden that drives malignancy. The finding that these pathways are subject to inherited, methylation-mediated regulation suggests that genetic susceptibility to colon cancer may operate in part by tuning the epigenetic setting of core cellular processes rather than by altering protein-coding sequences themselves.

Perhaps the most clinically resonant result concerns known colorectal cancer risk loci. Genome-wide association studies have identified dozens of genomic regions linked to colorectal cancer risk, but for most of them the causal gene and mechanism remain unknown. The new meQTL map covers 86.6 percent of previously identified CRC GWAS risk loci, and 40 percent of those covered loci showed significant colocalization with methylation signals. This means that for a substantial fraction of known risk regions, there is now a concrete, testable hypothesis about mechanism: the risk variant acts by altering methylation at nearby CpG sites, which in turn changes gene expression. For researchers hunting the functional consequences of GWAS hits, this resource converts a long list of anonymous risk loci into a ranked set of variant-CpG-gene triads to interrogate experimentally.

The study also fills an important demographic gap. Most large-scale meQTL resources, such as those derived from the Biobank Japan consortium or European-ancestry cohorts, reflect populations whose variant frequencies and linkage disequilibrium patterns differ from those of other groups. By building the catalog in an East Asian cohort of colon cancer patients, the team has created a reference that should improve the transferability of genetic risk prediction and functional interpretation to populations that have been underrepresented in cancer genomics. The authors describe the resulting dataset as a comprehensive resource integrating genetic, epigenomic, and transcriptomic information on colon cancer, revealing co-regulation of methylation and gene expression at single-base resolution across the genome.

The broader significance of the work lies in how it reframes the relationship between genetics and epigenetics in cancer. For years, DNA methylation changes in tumors were often treated as secondary consequences of transformation, downstream noise accompanying the driving mutations. This study argues for a more structured picture: a large portion of the tumor methylome is under direct genetic control, that control is pleiotropic and distributed, and it channels a substantial share of inherited risk into altered gene expression through defined molecular pathways. With the full dataset openly available as an open-access publication, other teams can now overlay their own GWAS results, test candidate variants for methylation-mediated effects, and design experiments around the specific CpG-gene links the map exposes. As multi-omics cohorts grow and similar maps are built for other cancers and populations, the colon cancer meQTL atlas stands as a template for turning epigenomic noise into mechanistic insight, one methylated cytosine at a time.

Subject of Research: Genetic regulation of DNA methylation in colon cancer through genome-wide meQTL mapping

Article Title: Genome-wide meQTL mapping reveals genetic control of DNA methylation in colon cancer

Article References: Hou, H., Zhou, Y., Chen, X., Luo, S., Yang, B., Peng, L., Tang, X., Yang, H., Wu, X., Liu, D., & Wu, K. (2026). Genome-wide meQTL mapping reveals genetic control of DNA methylation in colon cancer. Genome Medicine. https://doi.org/10.1186/s13073-026-01766-z

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01766-z

Keywords: colon cancer, DNA methylation, meQTL, epigenetics, whole-genome sequencing, whole-genome bisulfite sequencing, GWAS, colorectal cancer, gene expression, multi-omics, eQTL, cancer genomics